Shots:

• The first patient has been enrolled in a P-II trial to evaluate the safety & efficacy of JZP150 in 270 patients aged 18 to 70yrs. with PTSD across 40 US study sites. The results are expected in YE 2023
• The 1EPs of the trial measures patients change from the start to end of treatment using CAPS-5 score & has multiple 2EPs including changes in scores on the clinical global impressions severity and the patient global impression of severity scales from study start to the end of treatment
• JZP150 is a highly selective inhibitor of FAAH enzyme & has received FTD from the US FDA for PTSD. If approved, JZP150 will be 1st approved product for patients with the same indication

Ref: Jazz | Image: Jazz